iRadimed
IRMD
113 hedge funds and large institutions have $271M invested in iRadimed in 2023 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 48 increasing their positions, 34 reducing their positions, and 14 closing their positions.
41% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 34
7% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 14
1% more funds holding
Funds holding: 112 → 113 (+1)
0.48% less ownership
Funds ownership: 48.71% → 48.23% (-0.48%)
8% less capital invested
Capital invested by funds: $293M → $271M (-$22.2M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| 1 |
BlackRock
New York
|
+$5.47M |
| 2 |
Millennium Management
New York
|
+$1.48M |
| 3 |
BCC
Bridge City Capital
Lake Oswego,
Oregon
|
+$1.31M |
| 4 |
Swiss National Bank
Zurich,
Switzerland
|
+$771K |
| 5 |
Morgan Stanley
New York
|
+$651K |
Top Sellers
IRMD Hedge Fund Activity: Q3 2023 in Review
113 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in iRadimed (IRMD) for Q3 2023, worth a combined $271M — down 7.6% from $293M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new IRMD positions and 14 closed out — a net gain of 1 holder — while 48 added to existing stakes and 34 trimmed.
The largest buyer was BlackRock, adding an estimated $5.47M. The largest seller was Soleus Capital Management, cutting an estimated $6.76M.
- 113 institutional investors held iRadimed (IRMD) as of Q3 2023, up from 112 in Q2 2023.
- Funds reported $271M of iRadimed stock for Q3 2023, down 7.6% quarter-over-quarter.
- 15 funds opened new iRadimed positions in Q3 2023 and 14 closed out, a net change of +1 holder.
- The largest iRadimed buyer in Q3 2023 was BlackRock, an estimated $5.47M added.
- The largest iRadimed seller in Q3 2023 was Soleus Capital Management, an estimated $6.76M sold.
Based on aggregated 13F filings for Q3 2023.